Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q2 FY2019 Earnings Presentation
14 slides from Thyrocare Technologies's earnings presentation, 2018
Slide 1: Thyrocare Technologies Limited Investor Presentation Q2 FY 2018-2019
Thyrocare Technologies Limited Investor Presentation Q2 FY 2018-2019
Slide 2: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 3: Buyback of Equity shares
Buyback of Equity shares Buyback by Thyrocare Technologies Limited (“Company”) of its fully paid-up equity shares each having a face value of Rs. 10 each (“Equity Shares”) from the open market through stock exchange mechanism (“Buyback”) in accordance with the Securities and Exchange Board of India
Slide 4: Consolidated financial highlights Quarter ended September 2018
Consolidated financial highlights Quarter ended 30 September 2018 18%▲ 22%▲ 42% Consolidated Consolidated Consolidated Revenue QoQ EBITDA QoQ EBITDA Margin Growth in revenue in pathology segment revived back after the base year impact 14% of earlier periods, this coupled with growth in radiology s
Slide 5: Thyrocare Standalone financial highlights Quarter ended September 2018
Thyrocare Standalone financial highlights Quarter ended 30 September 2018 17%▲ 21%▲ 43% Standalone - Standalone - Standalone - Thyrocare Thyrocare Thyrocare Revenue QoQ EBITDA QoQ EBITDA Margin Growth in revenue in pathology segment is evidenced mainly in B2B and B2C in 13% this quarter with preve
Slide 6: Nueclear Standalone financial highlights Quarter ended September 2018
Nueclear Standalone financial highlights Quarter ended 30 September 2018 31%▲ 22%▲ 23% Standalone - Standalone - Standalone - Nueclear Nueclear Nueclear Revenue QoQ EBITDA QoQ EBITDA Margin Growth in revenue in radiology segment is evidenced mainly with newer centers maturing and the matured cente
Slide 7: Thyrocare Operational Performance
Thyrocare Operational Performance 4.94 million samples tested ▲ 21% QoQ. Of which 4.38 million were B2B samples ▲ 17% QoQ B2B revenue of Rs. Preventivecare revenue of 71.35cr ▲ 23% QoQ Rs.49.67cr ▲23% QoQ B2C revenue of Rs. 20.05 cr Sickcare revenue Rs. 41.72 cr ▲ 9% QoQ ▲ 16% QoQ 26.17 million DSA
Slide 8: Thyrocare Operational Performance continued
Thyrocare Operational Performance continued…… Operational information Part iculars Quart er Endded Qt r. Six Mont hs Ended Six 30 September 30 June 30 September YOY (%) 30 September 30 September Mont h 2018 2018 2017 2018 2017 YOY (%) B2B revenue (in crore) 71.35 66.17 57.93 23 137.51 113.37 21 B2C
Slide 9: Thyrocare Standalone Financials reported
Thyrocare Standalone Financials reported Thyrocare (Rs. in crore, except per share data) Part iculars Quart er Endded Qt r. Six Mont hs Ended Six 30 September 30 June 30 September YOY (%) 30 September 30 September Mont h 2018 2018 2017 2018 2017 YOY (%) Revenue from operations 95.68 89.19 81.79 17 1
Slide 10: Nueclear Operational Performance
Nueclear Operational Performance DELHI MUMBAI Delhi – 1,439 scans Mumbai – 2,574 PET , 578 CT [2 PET scanners] scans [2 centers / 3 PET scanners] 1439 2,574 scans scans HYDERABAD 947 PET 953 1,275 SURAT/ VADODRA scans scans [1 PET scanner] 1,168 PET , 107 CT scans [2 centers / 2 PET scanners] 8,208
Slide 11: Nueclear Operational Performance continued
Nueclear Operational Performance continued…… [Revenue in crore] Particulars Quarter ended Six Months ended 30 September 30 June 30 September 30 September 30 September 2018 2018 2017 2018 2017 Reported PET scans - Total 7509 7242 5508 14751 11070 Mumbai 2574 2462 1828 5036 3787 Delhi 1439 1572 1836 3
Slide 12: Nueclear Standalone Financials
Nueclear Standalone Financials Nueclear (Rs. in crore, except per share data) Part iculars Quart er Endded Qt r. Six Mont hs Ended Six 30 September 30 June 30 September YOY (%) 30 September 30 September Mont h 2018 2018 2017 2018 2017 YOY (%) Revenue from operations 8.19 7.96 6.25 31 16.15 11.87 36
Slide 13: Thyrocare Consolidated Financials reported
Thyrocare Consolidated Financials reported Thyrocare [Consolidated] (Rs. in crore, except per share data) Part iculars Quart er Endded Qt r. Six Mont hs Ended Six 30 September 30 June 30 September YOY (%) 30 September 30 September Mont h 2018 2018 2017 2018 2017 YOY (%) Revenue from operations 103.8
Slide 14: Thank You
Thyrocare’ Think Thyroid. Think Thyrocare. THANK YOU
Thyrocare Technologies — Q2 FY2019 Earnings Presentation on 6ix